MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...
In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...
In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has updated employment agreements with key executive officers, including ...
MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
Agteria Biotech, a company focused on cutting global greenhouse gas emissions by 1 per cent, has secured €6M in a seed round of funding.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback